GSK announces data from five Phase III studies of albiglutide
24 June 2013 | By GlaxoSmithKline
Data from five long-term Phase III studies comparing albiglutide...
List view / Grid view
24 June 2013 | By GlaxoSmithKline
Data from five long-term Phase III studies comparing albiglutide...
24 June 2013 | By Novo Nordisk
Key results from the global Diabetes Attitudes, Wishes and Needs 2 study (DAWN2™)...
24 June 2013 | By Novartis
Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel®)...
24 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the submission of an application to the EMA...
22 June 2013 | By Novo Nordisk
Findings from a new real-world study...
22 June 2013 | By Sanofi
Topline results of EDITION II consistent with EDITION I findings...
21 June 2013 | By kdm communications limited
Fledgling spin-out company Drop-Tech has turned to microfluidics specialist Dolomite for its product development and fabrication skills...
21 June 2013 | By Novartis
RLX030 has the potential to address a serious unmet medical need...
20 June 2013 | By H. Lundbeck A/S
Lundbeck's initiative could lead to a reduction of around 50-55 positions in Europe...
20 June 2013 | By A*STAR Institute of Chemical and Engineering Sciences (ICES)
New programme aims to increase productivity with technology solutions for pharmaceutical and chemical sectors...
20 June 2013 | By Abbott
Abbott has introduced the first FDA-approved HCV genotyping test...
20 June 2013 | By Bristol-Myers Squibb Company
Data added to Sprycel U.S. labeling are among the longest follow-up data of current CML treatment options...
19 June 2013 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb announced top-line results...
19 June 2013 | By Sanofi
Preclinical program of translational research to identify new target proteins...
18 June 2013 | By GlaxoSmithKline
GlaxoSmithKline has received an offer for its thrombosis brands...